Epigenomics AG

Epigenomics AG (FRA:ECX) Epigenomics AG / Miscellaneous cooperation, Contract / Ad hoc: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG Signs Strategic R&D Collaboration Agreement in Colorectal Cancer with Sysmex Corporation Ad hoc announcement according to §15 WpHG processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Epigenomics AG (FRA:ECX) - Focus on detection of methylated DNA in blood using Sysmex instrumentation - Sysmex assay system to be benchmarked against Epigenomics' mSEPT9 assay - Parties entered into negotiations for a non-exclusive IVD license to mSEPT9 colorectal cancer blood test Berlin, Germany, and Kobe, Japan, January 22, 2009 - Sysmex Corporation (HQ: Kobe Japan; President: Hisashi Ietsugu) and Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A0BVT96) announced today that they have signed a strategic research and development collaboration agreement in molecular diagnostics.

Epigenomics AG (FRA:ECX) Epigenomics AG / Miscellaneous cooperation, License / Ad hoc: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG and Philips Collaborate on Integrated Automation Solutions for DNA Methylation-based Cancer Diagnostics Ad hoc announcement according to §15 WpHG processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Epigenomics AG (OJ:ECX) Epigenomics AG / Contract / Ad hoc: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG and Abbott Molecular Inc. Expand Strategic In Vitro Diagnostics Partnership Ad hoc announcement according to §15 WpHG processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Epigenomics AG (OJ:ECX) Key Figures (in EUR thousand)

Epigenomics AG (OJ:ECX) - Successfully qualified 17 PRESEPT clinical sites; 12 sites initiated - Enrollment nearly 500 hundred subjects in first three months - Expanded clinical site network to include first site in Germany - Launched PRESEPT Study website found at www.presept.net - Added Prof. Dr. Thomas Rösch to the Clinical Study Steering Committee - Appointed Dr. Timothy R. Church responsible for study results analysis - Clinical Study Steering Committee recommends strengthening design by dropping interim analysis

Epigenomics AG (OJ:ECX) - Clinical study with patient cohorts from multiple clinical centers completed - All study endpoints met - PITX2 biomarker classifies patients into groups at high and low risk for relapse

Epigenomics AG (OJ:ECX) Epigenomics AG / Voting rights: Correction Release of a Voting Rights Notification (§ 21 para. 1 WpHG) released on 11 September 2008 in Accordance with § 26, para. 1 WpHG (German Securities Trading Act) with the Aim of an Europe-wide Distribution Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Epigenomics AG (OJ:ECX) Epigenomics AG / Voting rights: Voting Rights: Release of a Voting Rights Notification (§ 21 para. 1 WpHG) in Accordance with § 26, para. 1 WpHG (German Securities Trading Act) with the Aim of an Europe-wide Distribution Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Epigenomics AG (OJ:ECX) - Clinical study of over 500 patient samples well on track for completion in Q4 2008 - Interim analysis representing approximately half of the cases demonstrates statistical significance for primary endpoint of prostate cancer prognosis (probability of recurrence) - PITX2 biomarker classifies patients into groups at high and low risk for relapse following surgery